ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,734.17
      -0.19%
      US Tech 100
      19,496.40
      -0.42%
      Dow Jones
      42,329.64
      0.37%
      Brent Oil
      71.515
      0.80%
      Bitcoin
      65,598.19
      0.63%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Sanofi (SAN)

      7. Sanofi (SAN) News

      SAN

      Sanofi (SAN)

      Sanofi
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:SAN
      DateTimeSourceHeadlineSymbolCompany
      09/27/20249:35AMGlobeNewswire Inc.Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPDEU:SANSanofi
      09/27/20249:35AMGlobeNewswire Inc.Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPDEU:SANSanofi
      09/27/20247:00AMGlobeNewswire Inc.Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)EU:SANSanofi
      09/27/20247:00AMGlobeNewswire Inc.Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPDEU:SANSanofi
      09/26/20241:30AMGlobeNewswire Inc.Press Release: Availability of the Q3 2024 Aide mémoireEU:SANSanofi
      09/20/20246:36PMGlobeNewswire Inc.Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplantEU:SANSanofi
      09/20/20247:45AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year oldEU:SANSanofi
      09/20/20245:30AMGlobeNewswire Inc.Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 studyEU:SANSanofi
      09/13/202412:15PMGlobeNewswire Inc.Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)EU:SANSanofi
      09/12/20241:00AMGlobeNewswire Inc.Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancersEU:SANSanofi
      09/02/20241:00AMGlobeNewswire Inc.Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosisEU:SANSanofi
      08/08/20241:00AMGlobeNewswire Inc.Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplantEU:SANSanofi
      07/25/202410:56AMGlobeNewswire Inc.Press Release: Online availability of Sanofi’s half-year financial report for 2024EU:SANSanofi
      07/25/20241:30AMGlobeNewswire Inc.Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgradedEU:SANSanofi
      07/17/20245:27PMGlobeNewswire Inc.Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia AEU:SANSanofi
      07/03/20241:00AMGlobeNewswire Inc.Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenneEU:SANSanofi
      07/03/20241:00AMGlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDEU:SANSanofi
      07/03/20241:00AMGlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDEU:SANSanofi
      06/26/20245:30PMGlobeNewswire Inc.Communiqué de presse : Publication dans le NEJM des données positives de phase III du Dupixent dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 12 mois à 11 ansEU:SANSanofi
      06/26/20245:30PMGlobeNewswire Inc.Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJMEU:SANSanofi
      06/26/20245:30PMGlobeNewswire Inc.Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJMEU:SANSanofi
      06/25/20241:32PMGlobeNewswire Inc.Press Release: Availability of the Q2 2024 Aide-mémoireEU:SANSanofi
      06/25/20241:32PMGlobeNewswire Inc.Communiqué de presse : Mise en ligne du document « Aide-mémoire Q2 2024 »EU:SANSanofi
      06/21/20243:30AMGlobeNewswire Inc.Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive CommitteeEU:SANSanofi
      06/21/20243:30AMGlobeNewswire Inc.Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive CommitteeEU:SANSanofi
      06/21/20243:30AMGlobeNewswire Inc.Communiqué de presse : Audrey Duval Derveloy nommée Directrice Affaires Corporate Groupe, membre du Comité exécutif de SanofiEU:SANSanofi
      06/21/20241:00AMGlobeNewswire Inc.Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiranEU:SANSanofi
      06/21/20241:00AMGlobeNewswire Inc.Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiranEU:SANSanofi
      06/21/20241:00AMGlobeNewswire Inc.Communiqué de presse : ISTH : De nouvelles données sur ALTUVIIIO et le fitusiran confortent le leadership de Sanofi dans le traitement de l’hémophilieEU:SANSanofi
      06/20/20248:00AMGlobeNewswire Inc.Communiqué de presse : Sanofi et Biovac pionniers de la production de vaccins contre la polio en AfriqueEU:SANSanofi
       Showing the most relevant articles for your search:EU:SAN